Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease

Lauren B Elman, MD
Leo McCluskey, MD, MBE
Section Editor
Jeremy M Shefner, MD, PhD
Deputy Editor
John F Dashe, MD, PhD


Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive, presently incurable, neurodegenerative disorder that causes muscle weakness, disability, and eventually death.

This topic will review the clinical evaluation and laboratory testing needed to support the diagnosis of ALS and other forms of motor neuron disease, as well as the differential diagnosis of ALS. Other aspects of ALS are discussed separately. (See "Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease" and "Epidemiology and pathogenesis of amyotrophic lateral sclerosis" and "Familial amyotrophic lateral sclerosis" and "Symptom-based management of amyotrophic lateral sclerosis" and "Disease modifying treatment of amyotrophic lateral sclerosis".)


ALS is one of multiple degenerative motor neuron diseases that are clinically defined, based on the involvement of upper and/or lower motor neurons. ALS is the most common form of motor neuron disease. The diagnosis of ALS is based upon clinical criteria that include the presence of upper motor neuron and lower motor neuron signs, progression of disease, and the absence of an alternative explanation. There is no single diagnostic test that can confirm or entirely exclude the diagnosis of motor neuron disease.

Practically speaking, clinicians make the diagnosis of ALS when it is suggested by the history and physical examination, supported by electrodiagnostic studies, and not excluded by neuroimaging and laboratory studies.

History — The diagnosis of ALS is suggested when there are progressive symptoms consistent with upper and lower motor neuron dysfunction that present in one of four body segments (cranial/bulbar, cervical, thoracic, and lumbosacral) followed by spread to other segments over a period of months to years. The course is not relapsing and remitting, but rather is insidiously progressive. Involuntary weight loss and muscle wasting unrelated to nutrition may also occur.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: May 18, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Lomen-Hoerth C. Characterization of amyotrophic lateral sclerosis and frontotemporal dementia. Dement Geriatr Cogn Disord 2004; 17:337.
  2. Strong MJ, Lomen-Hoerth C, Caselli RJ, et al. Cognitive impairment, frontotemporal dementia, and the motor neuron diseases. Ann Neurol 2003; 54 Suppl 5:S20.
  3. Lomen-Hoerth C, Murphy J, Langmore S, et al. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60:1094.
  4. Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002; 59:1077.
  5. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. In: Contemporary Neurology Series, 49, F.A. Davis Company, Philadelphia 1998.
  6. LANDAU WM, CLARE MH. The plantar reflex in man, with special reference to some conditions where the extensor response is unexpectedly absent. Brain 1959; 82:321.
  7. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 1994; 124 Suppl:96.
  8. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1:293.
  9. Chaudhuri KR, Crump S, al-Sarraj S, et al. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinicopathological study. J Neurol Sci 1995; 129 Suppl:11.
  10. Forbes RB, Colville S, Swingler RJ. Are the El Escorial and Revised El Escorial criteria for ALS reproducible? A study of inter-observer agreement. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2:135.
  11. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119:497.
  12. Ross MA, Miller RG, Berchert L, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis: revised criteria. rhCNTF ALS Study Group. Neurology 1998; 50:768.
  13. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: A population-based study. Arch Neurol 2000; 57:1171.
  14. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 2012; 69:1410.
  15. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006; 66:647.
  16. Wijesekera LC, Mathers S, Talman P, et al. Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009; 72:1087.
  17. Daube JR. Electrodiagnostic studies in amyotrophic lateral sclerosis and other motor neuron disorders. Muscle Nerve 2000; 23:1488.
  18. Krivickas LS. Amyotrophic lateral sclerosis and other motor neuron diseases. Phys Med Rehabil Clin N Am 2003; 14:327.
  19. de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 2000; 23:344.
  20. Olney RK, Lomen-Hoerth C. Motor unit number estimation (MUNE): how may it contribute to the diagnosis of ALS? Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2:S41.
  21. Shefner JM, Gooch CL. Motor unit number estimation in neurologic disease. Adv Neurol 2002; 88:33.
  22. Gooch CL, Shefner JM. ALS surrogate markers. MUNE. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5 Suppl 1:104.
  23. de Carvalho M, Scotto M, Lopes A, Swash M. Quantitating progression in ALS. Neurology 2005; 64:1783.
  24. Shefner JM. Amyotrophic lateral sclerosis. In: Office Practice of Neurology, 2nd ed, Samuels, MA, Feske, SK (Eds), Churchill Livingstone, Philadelphia 2003. p.548.
  25. LAMBERT EH, MULDER DW. Electromyographic studies in amyotrophic lateral sclerosis. Proc Staff Meet Mayo Clin 1957; 32:441.
  26. MULDER DW, LAMBERT EH, EATON LM. Myasthenic syndrome in patients with amyotrophic lateral sclerosis. Neurology 1959; 9:627.
  27. Henderson RD, Daube JR. Decrement in surface-recorded motor unit potentials in amyotrophic lateral sclerosis. Neurology 2004; 63:1670.
  28. Jillapalli D, Shefner JM. Single motor unit variability with threshold stimulation in patients with amyotrophic lateral sclerosis and normal subjects. Muscle Nerve 2004; 30:578.
  29. Wang FC, De Pasqua V, Gérard P, Delwaide PJ. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients. Neurology 2001; 57:897.
  30. Killian JM, Wilfong AA, Burnett L, et al. Decremental motor responses to repetitive nerve stimulation in ALS. Muscle Nerve 1994; 17:747.
  31. Denys EH, Norris FH Jr. Amyotrophic lateral sclerosis. Impairment of neuromuscular transmission. Arch Neurol 1979; 36:202.
  32. Brown WF, Jaatoul N. Amyotrophic lateral sclerosis. Electrophysiologic study (number of motor units and rate of decay of motor units). Arch Neurol 1974; 30:242.
  33. Carleton SA, Brown WF. Changes in motor unit populations in motor neurone disease. J Neurol Neurosurg Psychiatry 1979; 42:42.
  34. Cui LY, Liu MS, Tang XF. Single fiber electromyography in 78 patients with amyotrophic lateral sclerosis. Chin Med J (Engl) 2004; 117:1830.
  35. Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol 2011; 122:1860.
  36. Pohl C, Block W, Träber F, et al. Proton magnetic resonance spectroscopy and transcranial magnetic stimulation for the detection of upper motor neuron degeneration in ALS patients. J Neurol Sci 2001; 190:21.
  37. Schulte-Mattler WJ, Müller T, Zierz S. Transcranial magnetic stimulation compared with upper motor neuron signs in patients with amyotrophic lateral sclerosis. J Neurol Sci 1999; 170:51.
  38. Kaufmann P, Mitsumoto H. Amyotrophic lateral sclerosis: objective upper motor neuron markers. Curr Neurol Neurosci Rep 2002; 2:55.
  39. Kaufmann P, Pullman SL, Shungu DC, et al. Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology 2004; 62:1753.
  40. Pouget J, Trefouret S, Attarian S. Transcranial magnetic stimulation (TMS): compared sensitivity of different motor response parameters in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1 Suppl 2:S45.
  41. Miscio G, Pisano F, Mora G, Mazzini L. Motor neuron disease: usefulness of transcranial magnetic stimulation in improving the diagnosis. Clin Neurophysiol 1999; 110:975.
  42. Floyd AG, Yu QP, Piboolnurak P, et al. Transcranial magnetic stimulation in ALS: utility of central motor conduction tests. Neurology 2009; 72:498.
  43. Menon P, Geevasinga N, Yiannikas C, et al. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol 2015; 14:478.
  44. Chan S, Shungu DC, Douglas-Akinwande A, et al. Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 1999; 212:763.
  45. Oba H, Araki T, Ohtomo K, et al. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 1993; 189:843.
  46. Turner MR, Grosskreutz J, Kassubek J, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol 2011; 10:400.
  47. Wang S, Melhem ER, Poptani H, Woo JH. Neuroimaging in amyotrophic lateral sclerosis. Neurotherapeutics 2011; 8:63.
  48. Verma G, Woo JH, Chawla S, et al. Whole-brain analysis of amyotrophic lateral sclerosis by using echo-planar spectroscopic imaging. Radiology 2013; 267:851.
  49. Hornberger M, Kiernan MC. Emergence of an imaging biomarker for amyotrophic lateral sclerosis: is the end point near? J Neurol Neurosurg Psychiatry 2016; 87:569.
  50. Govind V, Sharma KR, Maudsley AA, et al. Comprehensive evaluation of corticospinal tract metabolites in amyotrophic lateral sclerosis using whole-brain 1H MR spectroscopy. PLoS One 2012; 7:e35607.
  51. Stagg CJ, Knight S, Talbot K, et al. Whole-brain magnetic resonance spectroscopic imaging measures are related to disability in ALS. Neurology 2013; 80:610.
  52. Pierpaoli C, Basser PJ. Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996; 36:893.
  53. Basser PJ, Pajevic S, Pierpaoli C, et al. In vivo fiber tractography using DT-MRI data. Magn Reson Med 2000; 44:625.
  54. Iwata NK, Aoki S, Okabe S, et al. Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 2008; 70:528.
  55. Menke RA, Abraham I, Thiel CS, et al. Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Arch Neurol 2012; :1.
  56. Filippini N, Douaud G, Mackay CE, et al. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010; 75:1645.
  57. Müller HP, Turner MR, Grosskreutz J, et al. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2016; 87:570.
  58. Jackson CE, Amato AA, Bryan WW, et al. Primary hyperparathyroidism and ALS: is there a relation? Neurology 1998; 50:1795.
  59. Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.
  60. Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 2009; 256:615.
  61. Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87:12.
  62. Misawa S, Noto Y, Shibuya K, et al. Ultrasonographic detection of fasciculations markedly increases diagnostic sensitivity of ALS. Neurology 2011; 77:1532.
  63. Cartwright MS, Walker FO, Griffin LP, Caress JB. Peripheral nerve and muscle ultrasound in amyotrophic lateral sclerosis. Muscle Nerve 2011; 44:346.
  64. Swash M, Carvalho Md. Muscle ultrasound detects fasciculations and facilitates diagnosis in ALS. Neurology 2011; 77:1508.
  66. Mitsikostas DD, Karandreas N, Coutsopetras P, et al. Fasciculation potentials in healthy people. Muscle Nerve 1998; 21:533.
  67. de Carvalho M, Swash M. Fasciculation potentials: a study of amyotrophic lateral sclerosis and other neurogenic disorders. Muscle Nerve 1998; 21:336.
  68. Blexrud MD, Windebank AJ, Daube JR. Long-term follow-up of 121 patients with benign fasciculations. Ann Neurol 1993; 34:622.
  69. Sunnerhagen KS, Grimby G. Muscular effects in late polio. Acta Physiol Scand 2001; 171:335.
  70. Chasens ER, Umlauf MG. Post-polio syndrome. Am J Nurs 2000; 100:60.
  71. Rowland LP. Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve 2010; 41:161.
  72. HIRAYAMA K, TSUBAKI T, TOYOKURA Y, OKINAKA S. Juvenile muscular atrophy of unilateral upper extremity. Neurology 1963; 13:373.
  73. Hirayama K. [Juvenile non-progressive muscular atrophy localized in the hand and forearm--observations in 38 cases]. Rinsho Shinkeigaku 1972; 12:313.
  74. Pradhan S. Bilaterally symmetric form of Hirayama disease. Neurology 2009; 72:2083.
  75. Hosokawa T, Fujieda M, Wakiguchi H, Oosaki Y. Pediatric Hirayama disease. Pediatr Neurol 2010; 43:151.
  76. Hirayama K, Tomonaga M, Kitano K, et al. Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity: a pathological study. J Neurol Neurosurg Psychiatry 1987; 50:285.
  77. O'Sullivan DJ, McLeod JG. Distal chronic spinal muscular atrophy involving the hands. Clin Exp Neurol 1977; 14:256.
  78. Di Muzio A, Delli Pizzi C, Lugaresi A, et al. Benign monomelic amyotrophy of lower limb: a rare entity with a characteristic muscular CT. J Neurol Sci 1994; 126:153.
  79. Gourie-Devi M, Nalini A. Long-term follow-up of 44 patients with brachial monomelic amyotrophy. Acta Neurol Scand 2003; 107:215.
  80. Verma A, Bradley WG. Atypical motor neuron disease and related motor syndromes. Semin Neurol 2001; 21:177.
  81. Sobue I, Saito N, Iida M, Ando K. Juvenile type of distal and segmental muscular atrophy of upper extremities. Ann Neurol 1978; 3:429.
  82. Tandan R, Sharma KR, Bradley WG, et al. Chronic segmental spinal muscular atrophy of upper extremities in identical twins. Neurology 1990; 40:236.
  83. Nalini A, Lokesh L, Ratnavalli E. Familial monomelic amyotrophy: a case report from India. J Neurol Sci 2004; 220:95.
  84. Finsterer J. Perspectives of Kennedy's disease. J Neurol Sci 2010; 298:1.
  85. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77.
  86. Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011; 377:942.